Tff Pharmaceuticals, Inc. Stock Price, News & Analysis

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) will release its fourth quarter 2021 financial results and business update on March 24, 2022, following the close of U.S. markets. A conference call is scheduled for the same day at 4:30 PM ET, where management will discuss financial results and recent corporate developments. Investors can join via a toll-free number or webcast, with a question-and-answer session following the presentation. The company focuses on innovative drug products using its patented Thin Film Freezing technology, enhancing the delivery of poorly water-soluble drugs.

TFF Pharmaceuticals (NASDAQ: TFFP) has announced a collaboration with Catalent to enhance the scalability and manufacturing of its proprietary Thin Film Freezing (TFF) technology. This agreement aims to develop dry powder formulations for biotherapeutics, particularly focusing on inhaled delivery systems. Catalent will utilize its expertise in dry powder development to support TFFP's technology, potentially increasing the adoption of pulmonary drug delivery. This partnership is expected to expand TFFP’s manufacturing capabilities and open opportunities for technology licensing.

TFF Pharmaceuticals (NASDAQ: TFFP) announced promising results from its inhaled niclosamide product against COVID-19 variants, Delta and Omicron. The in vitro assays revealed complete viral replication inhibition at concentrations as low as 1μM, outperforming other treatments like nirmatrelvir. A Phase 1 trial showed the 6 mg dosage is well tolerated, producing effective concentrations in lung fluid. The company anticipates delivering safety and pharmacokinetic data by the end of Q1 2022, enhancing confidence in niclosamide's therapeutic potential against COVID-19 in vulnerable populations.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced the completion of enrollment in its Phase 1 clinical trial of a dry powder formulation of niclosamide, aimed at treating COVID-19 and respiratory viral diseases. The trial included 40 healthy subjects, with safety results expected by the end of Q1 2022. The Safety Management Committee has recommended a 12 mg daily dose for Phase 2 testing. Niclosamide has shown potential against SARS-CoV-2 variants, with a previous study reporting a seven-fold reduction in viral load in treated models. UNION Therapeutics holds an option for exclusive licensing of the formulation.

TFF Pharmaceuticals (TFFP) has announced the full readout of safety and pharmacokinetic data from its Phase 1b study of Inhaled Voriconazole Powder (TFF VORI) in asthma patients. The study shows TFF VORI is well tolerated, with no differences in drug absorption between asthma and healthy patients. The company plans to advance to Phase 2 trials in 2022, potentially expanding the treatment to Allergic Bronchopulmonary Aspergillosis. TFF Pharmaceuticals aims to improve efficacy and safety of IPA treatment through direct lung delivery, enhancing patient outcomes.

TFF Pharmaceuticals (NASDAQ: TFFP) reported substantial progress in its clinical and corporate developments during Q3 2021, with significant advancements in its Inhaled Voriconazole and Tacrolimus programs, which are set to enter Phase 2 trials by year-end. The company also noted positive outcomes in its partnerships for antiviral programs, particularly AUG-3387 and niclosamide, with the latter's Phase 1 trial recently initiated. Financially, TFFP reported a net loss of $8.7 million, up from $5.1 million in Q3 2020, with R&D expenses increasing to $6.3 million from $2.8 million, reflecting ongoing investments in their drug development pipeline.

TFF Pharmaceuticals, Inc. announced positive results from its Phase 1b clinical trial for Voriconazole Inhalation Powder (TFF VORI), designed for the treatment of Invasive Pulmonary Aspergillosis (IPA) in asthma patients. The data indicates that TFF VORI is well tolerated, supporting the move to Phase 2 trials which may include patients with hyperreactive airway diseases. This development could also open avenues for treating Allergic Bronchopulmonary Aspergillosis (ABPA). The innovative TFF platform enhances drug delivery directly to the lungs, potentially improving efficacy and safety.

AUSTIN, Texas, Nov. 08, 2021 - TFF Pharmaceuticals (NASDAQ: TFFP) announced that President and CEO Glenn Mattes will present a corporate overview at the 12th Annual Jefferies London Healthcare Conference from November 16-19, 2021. The presentation will be available on demand starting November 18, 2021, at 3:00 AM ET. TFF Pharmaceuticals specializes in drug products using its patented Thin Film Freezing technology, which enhances the solubility and absorption of poorly water-soluble drugs.

The replay will be accessible for 30 days post-event on the Company’s website.